KABLA joins forces with SAMACAPITAL for the purpose of investing even more in rapid diagnosis tests.
Jul 10, 2018, 09:00 ET.
MONTERREY, Mexico, July 10th 2018 – Kabla Diagnosticos, industry leader in supplying innovative medical devices, teams up with SAMACAPITAL, a private investment fund from Monterrey, Mexico, with the purpose of increasing Kabla’s market share and accelerating their expansion process on its existing catalogue of alcohol meters, rapid tests, laboratory tests and “point-of-care” diagnosis solutions, along with entering new markets in the health sector and other scientific specialties.
Kabla is a leading mexican company in the distribution of in vitro diagnosis tests, offering highly differentiated products, competitive prices, and a customer-oriented approach to its clients. It has maintained its position at the industry’s forefront by integrating a very extensive product catalogue that consolidates brands from more than 15 countries. These brands’ manufacturers have trusted Kabla to be their exclusive supplier in Mexico. This new partnership agreement will enable Kabla to focus on offering more diagnosis solutions for clinical use, along with a bigger portfolio of medical devices, consumables, and instrumentation to meet the needs of Clinical Analysis Laboratories, Biocompatibility Analysis, Industrial/Food Analysis, Veterinary, Forensics, and Research and Development, among others.
On the other hand, SAMACAPITAL is a mexican investment fund whose main goal is to boost economic development by investing in high-impact projects on infrastructure, health, technology, hospitality, and entertainment. Through this investment, Kabla has become a key strategic partner in their long-term growth vision.
Since it was founded in 2004, Kabla’s mission has been to efficiently supply innovative products to health and safety professionals, allowing them to improve and increase the scope of their services by receiving good value in terms of quality, service, and price. Through this partnership, we intend to accelerate our expansion process to meet the growing demands of the markets in which we conduct business.